Zealand Pharma has filed a patent for pharmaceutical compositions with specific preservatives. The claim includes a formula for GLP-1/GLP-2 dual agonists and the use of m-cresol and/or phenol as preservatives along with tris buffer. GlobalData’s report on Zealand Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Zealand Pharma AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zealand Pharma, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Zealand Pharma's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240024425A1) discloses a composition comprising a GLP-1/GLP-2 dual agonist with a specific chemical structure, an albumin binding moiety, and a tris buffer. The composition also includes one or more preservatives, such as m-cresol and/or phenol. Additionally, the composition is formulated as an isotonic parenteral pharmaceutical composition, with the tris buffer present at a concentration ranging from about 5 mM to about 50 mM, and a pH between 6.0 to 8.5.

Furthermore, the composition may contain tonicity agents like mannitol or NaCl, with specific concentrations specified for each component. The GLP-1/GLP-2 dual agonist is present at a concentration of at least 1 mg/mL, with options for concentrations of about 2 mg/mL, 15 mg/mL, or 25 mg/mL. The preservatives m-cresol and phenol are included at defined concentrations, and the composition may also comprise chloride salts of specific GLP-1/GLP-2 dual agonists. Overall, the patent application outlines a detailed formulation for a pharmaceutical composition containing a GLP-1/GLP-2 dual agonist, preservatives, tonicity agents, and buffers, designed for parenteral administration.

To know more about GlobalData’s detailed insights on Zealand Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies